Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
South Korea’s JW Pharmaceutical has received a patent in Russia for a hair loss treatment currently under development, marking the first time that its candidate drug has been patented overseas.
The pharmaceutical firm received a patent for JW0061, its Wnt-targeted hair loss treatment, from Russia's Federal Service for Intellectual Property.
The patent covers a new heterocyclic inducer of the Wnt signaling pathway, including its base or isomer, and compositions containing it as an active ingredient.
JW has also submitted patent applications in more than ten nations, including the US, EU, Japan, and China.
JW0061 exhibits a novel method of action by directly binding to the GFRA1 protein in human hair dermal papilla cells, activating the Wnt signaling pathway. This is the first instance of a low-molecular-weight medication that describes the mechanism of hair growth that has been documented.
JW is now evaluating non-clinical toxicity in accordance with good laboratory practice with the intention of initiating clinical trials for JW0061 in the first half of 2024. Additionally, it collaborates on research projects with eminent dermatologists in the US.
JW plans to develop JW0061 as a new innovative drug that supplements or replaces existing hair loss treatments.
